Core Insights - Schrodinger Inc. is recognized as a promising investment in the cancer sector, showcasing strong revenue growth and a strategic shift towards a licensing model for more predictable revenue streams [1][3]. Financial Performance - Full-year revenue for 2025 increased by 23.3% to $255.9 million, with software revenue rising by 10.6% [3]. - Drug discovery revenue more than doubled to $56.4 million from $27.2 million in the previous year [3]. - Fourth-quarter revenue decreased by 1.2% year-over-year to $87.2 million, primarily due to a 13% decline in software revenue to $69.3 million [3]. - Drug discovery revenue in the fourth quarter surged to $18 million, up from $8.7 million in the same quarter of the prior year [3]. Profitability and Loss - The company's net loss for the full year decreased to $103.3 million from $187.1 million in 2024 [4]. - Schrodinger achieved profitability in the fourth quarter of FY25, reporting a net income of $32.5 million compared to a net loss of $40.2 million in the fourth quarter of 2024 [4]. Future Guidance - For 2026, the company projects software revenue between $218 million and $228 million, indicating a growth of 10-15% [5]. - Drug discovery revenue is anticipated to be in the range of $55 million to $65 million [5]. Company Overview - Schrodinger, Inc. operates as a healthcare technology company, providing a physics-based software platform for molecular simulation aimed at accelerating drug development and materials science [6].